Intensity Therapeutics

Intensity Therapeutics

Intensity Therapeutics was founded to address the challenge of inadequate drug distribution within solid tumors, a key barrier in oncology. The company's DfuseRx platform creates molecules that actively disperse into tumor tissue, aiming to unlock the therapeutic potential of existing and novel agents. The firm operates primarily in the United States, with its research and clinical operations housed in Connecticut. Intensity's lead asset, INT230-6, combines cisplatin and doxorubicin in a single formulation designed for intratumoral injection. Publicly disclosed Phase 1/2 data (per the company, 2023) indicated disease control in heavily pretreated sarcoma and breast cancer patients. The firm has also expanded into combination studies with Merck's Keytruda (pembrolizumab) in a Phase 2 trial (per ClinicalTrials.gov, 2023). The company's strategy relies on the DfuseRx platform as a technology bridge to other drugs, enabling co-administration or conjugation with a range of therapeutic payloads. The firm is a public company, trading on the Nasdaq under the symbol INTP. It reported $24.0 million in cash and equivalents as of December 31, 2023 (per SEC filing, March 2024). Intensity had approximately $5 million in debt outstanding as of the same date. The company's intellectual property portfolio includes multiple patents covering its platform technology and formulations. A structural differentiator is Intensity's focus on intratumoral injection as a delivery route to overcome the physical barriers of dense tumor microenvironments. This approach contrasts with conventional systemic chemotherapy and may reduce off-target toxicity while increasing local drug concentration. The firm's platform is designed to be agnostic to tumor type and partner drug, positioning it as a technical enabler for combination cancer therapy.